Endogenex

Endogenex is a clinical-stage medical device company focused on improving outcomes for individuals with type 2 diabetes. Their ReCET System, a novel endoscopic outpatient procedure, targets duodenal cellular pathology to initiate the body's natural regenerative process and improve metabolic function. This aims to help patients better control blood glucose levels and slow disease progression.

Funding Round: Series C

Funding Amount: $88M

Date: 25-Jun-2024

Investors: Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, undisclosed strategic lead investor, Intuitive Ventures, Longitude Capital, Mayo Clinic, Santé Ventures

Markets: Medical Device, Diabetes

HQ: Plymouth, Minnesota, United States

Founded: 2017

Website: https://www.endogenex.com/

LinkedIn: https://www.linkedin.com/company/endogenexinc

Twitter: https://twitter.com/endogenex

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/dyamx

Pitchbook: https://pitchbook.com/profiles/company/232325-11